The target of ‘Dasatinib’ is ‘Tyrosine-protein kinase ABL1’ (ABL1: BCRABL), the disease gene of ‘Leukemia, Acute Myeloid; Aml’ is ‘Mast/stem cell growth factor receptor Kit’ (KIT). Here, ABL1 is linked to leukemia.